JustAnswer のしくみ:

  • 専門家に質問
    知識豊富な専門家があらゆる質問にお答えするために常に待機しています。
  • 専門家が丁寧に対応
    E メールやサイト内オンラインメッセージなど、さまざまな手段で回答を通知。
    必要に応じてフォローアップの質問をすることもできます。
  • 満足度 100% 保証
    専門家からの回答を確認し評価をすることで、支払うかどうかを決めます。

wantaroに今すぐ質問する

wantaro
wantaro, 獣医師
カテゴリ:
満足したユーザー: 5195
経験:  小動物臨床10年
61996574
ここに 猫 に関する質問を入力してください。
wantaroがオンラインで質問受付中

回答いただいた薬は、かかりつけの犬猫病院の先生に相談すれば、処方してもらえますか。

解決済みの質問:

回答いただいた薬は、かかりつけの犬猫病院の先生に相談すれば、処方してもらえますか。
投稿: 4 年 前.
カテゴリ: 
専門家:  wantaro 返答済み 4 年 前.
おそらく処方してもらえると思います。

以下が参考文献です。


Interferon Alfa, Human Recombinant
previous | list all
(in-ter-feer-on)
Roferon-A®, Intron-A®
Immunomodulator
Prescriber Highlights
Cytokine used to alleviate clinical effects of certain viral diseases; little scientific info available to document safety/efficacy in small animals
Cautions: Preexisting autoimmune disease, severe cardiac disease, pulmonary disease, "brittle" diabetes, Herpes infections, hypersensitivity to the drug, or CNS disorders
Adverse Effects: In cats, adverse effects are apparently uncommon with PO; higher dosages given parenterally may cause malaise; fever, allergic reactions, myelotoxicity & myalgia are possible
Uses/Indications
Interferon alfa use in veterinary medicine has primarily been centered on its SC, or oral/buccal administration in cats to treat a variety of virus-induced diseases. Despite rapid antibody development when injected parenterally and little, if any, absorption after oral administration, the drug does appear to have some efficacy for certain diseases, either via direct antiviral action or more likely, an immunomodulatory effect. Interferon-alfa has been used in dogs for the adjunctive treatment of viral- or immunosuppression-related conditions, such as papillomas, pododermatitis, or digital keratomas. Some work has been done in dogs evaluating it as an adjunctive treatment for certain neoplastic diseases (e.g., hemangiosarcoma).

In summarizing the in vitro, controlled study and clinical efficacy status in vivo for human interferon-alfa use in virus infected cats, one author (Hartmann 2008) reports: High dose SC administration to cats does not appear to be clinically effective for FIV or FeLV infections. Low dose oral treatment does appear to have some efficacy for FIV in cats. Low dose oral therapy does not appear to be effective for FeLV, FHV-1, or FCV (feline calicivirus), and is contraindicated in FIP. Topical administration to FHV-1 infected cats may have some efficacy (see Topical Ophthalmology section). Feline Interferon-Omega has recently become available in several countries and it may be useful in treating viral diseases in both cats and dogs. A separate monograph for that agent follows this one.

Pharmacology/Actions
The pharmacologic effects of the interferons are widespread and complex. Suffice it to say, that interferon alfa has antiviral, antiproliferative, and immunomodulating effects. Its antiproliferative and antiviral activities are thought to be due to its effects on the synthesis of RNA, DNA, and cellular proteins (oncogenes included). The mechanisms for its antineoplastic activities are not well understood, but are probably related these effects as well.

Pharmacokinetics
Interferon alfa is poorly absorbed after oral administration due to its degradation by proteolytic enzymes and studies have not detected measurable levels in the systemic circulation, however, there may be some absorption via upper GI mucosa. It may have some immunomodulating effect via stimulation of local lymphoid tissues.

Interferon alfa is widely distributed throughout the body, although it does not penetrate into the CNS well. It is unknown if it crosses the placenta. Interferon alfa is freely filtered by the glomeruli, but is absorbed by the renal tubules where it is metabolized by brush border or lysosomes. Hepatic metabolism is of minor importance. The plasma half-life in cats has been reported as 2.9 hours.

Contraindications/Precautions/Warnings
When used parenterally, consider the risks versus benefits in patients with preexisting autoimmune disease, severe cardiac disease, pulmonary disease, "brittle" diabetes, Herpes infections, hypersensitivity to the drug, or CNS disorders.

One author states that low dose oral therapy is contraindicated in cats with FIP (Hartmann 2008).

Adverse Effects
When used orally in cats, adverse effects are apparently uncommon. Higher dosages given parenterally to cats may cause malaise; fever, allergic reactions, myelotoxicity, and myalgia are possible. Cats given human interferon-alfa parenterally may develop significant antibodies to it after 3–7 weeks of treatment with resultant loss of efficacy.

When used systemically in humans, adverse effects have included anemia, leukopenias, thrombocytopenia, hepatotoxicity, neurotoxicity, taste sensation changes, anorexia, nausea, vomiting, diarrhea, dizziness, "flu-like" syndrome, transient hypotension, skin rashes, and dry mouth. Except for the "flu-like "syndrome, most adverse effects are dose-related and may vary depending on the condition treated.

Reproductive/Nursing Safety
Safety during pregnancy has not been established; high parenteral doses in monkeys did not cause teratogenic effects, but did increase abortifacient activity. In humans, the FDA categorizes this drug as category C for use during pregnancy (Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in humans; or there are no animal reproduction studies and no adequate studies in humans.)

It is not known whether this drug is excreted in milk.

Overdosage/Acute Toxicity
No information was located. Determine dosages carefully.

Drug Interactions
The following drug interactions have either been reported or are theoretical in humans or animals receiving interferon and may be of significance in veterinary patients:

Acyclovir, Zidovudine, Vidarabine: Additive or synergistic antiviral effects may occur when interferon alfa is used in conjunction with zidovudine (AZT) or acyclovir. This effect does not appear to occur with vidarabine, although increased toxicities may occur. The veterinary significance of these potential interactions is unclear.
Doses
Dogs:
1. For cutaneus T-cell lymphoma and severe cases of oral/cutaneus papillomas: 1.5–2 million Units/m2 SC 3 times weekly (White 2000)
2. As an immunostimulant for the adjunctive treatment of certain dermatologic conditions (e.g., pododermatitis, papillomas, digital keratomas): 1000 Units PO once daily (given as 1000 Unit/mL solution). (Yu 2008)
Cats:
For treatment of virus infections:

1. FeLV-infected cats: Low dose: 30 Units per cat PO daily; 7 days on, 7 days off); Hi dose: 10,000–1,000,000 Units/kg SC once daily. Little in the way of large, controlled trials to determine which, if any, immunomodulating therapies (interferon or other agents) are likely to benefit FeLV-infected cats. (Levy 2004)
2. For FIV: 30 Units per cat PO daily; 7 days on, 7 days off (Barr & Phillips 2000)
3. For chronic FHV-1 infections: 30 Units per cat PO daily; 7 days on, 7 days off; repeat cycle. May also use topical ophthalmic therapy: one drop of 25–50 Units/mL of saline in affected eye(s) q4–6 hours. (Powell 2002)
4. For acute life-threatening FHV-1 infections in kittens: 10,000 Units/kg SC daily for up to 3 weeks (Lappin 2003)
Client Information
Owners should be made aware of the "investigational" nature of this compound and understand that efficacy and safety have not necessarily been established
Chemistry/Synonyms
Prepared from genetically engineered cultures of E. coli with genes from human leukocytes, interferon alfa-2a is commercially available as a sterile solution or sterile powder. Human interferon alfa is a complex protein that contains 165 or 166 amino acids.

Interferon may also be known as: IFN-alpha, interferon-alpha, Ro-22-8181 (interferon alfa-2a), Sch-30500 (interferon alfa-2b); there are many internationally registered trade names available.

Storage/stability
Commercially available products should be stored in the refrigerator; do not freeze the accompanying diluent. Do not expose solutions to room temperature for longer than 24 hours. Do not vigorously shake solutions.

An article proposing using this product in cats for the treatment of FeLV states that after dilution of 3 million Units in one liter of sterile saline the resultant solution remains active for years if frozen or for months if refrigerated. However, data corroborating this is apparently not available.

Compatibility/Compounding Considerations
To prepare a 3 Unit/mL solution for oral administration: Using the 3 million Unit vial (see below), dilute the entire contents into 100 mL of sterile water; mix well. Resulting solution contains approximately 30,000 Units/mL. Take 0.1 mL of this solution and add to one liter of sterile saline that has 4 mL of 25% albumin added to it. Albumin is optional but adds stability. Solution is now 3 Units/mL. Divide into aliquots of 15 mL and freeze, preferably at -70°C. Thaw as needed and keep refrigerated. Discard unused portion after 60 days. Discard unused 30,000 Units/mL solution within 2–3 hours of making initial dilutions.

Preparation of solution for 30 Units/mL oral administration: Using the 3 million Unit vial (see below), dilute the entire contents into a 1 L bag of sterile normal saline; mix well. Resulting solution contains approximately 3,000 Units/mL. Divide into aliquots of either 1 or 10 mL and freeze. By diluting further 100 fold (1 mL of 3000 Units/mL solution with 100 mL of sterile saline, or 10 mL with 1000 mL of sterile saline) a 30 Units/mL solution will result. Some have advised aliquoting the diluted solution into 1 mL volumes for freezing up to a year; defrost as necessary. Once defrosted, the drug can be refrigerated up to one week. Freezing the most dilute solutions is associated with loss in activity unless protein such as albumin (see above) is added during dilution (Greene et al. 2006).

Dosage Forms/Regulatory Status
Veterinary-Labeled Products: None
Human-Labeled Products:
Interferon Alfa-2a (recombinant rIFN-A; IFLrA) Injection: Prefilled syringes: 3 million I.U./syringe (0.5 mL single-use syringes); 6 million I.U./syringe (0.5 mL single-use syringes); 9 million I.U./syringe (0.5 mL single-use syringes); Roferon-A® (Hoffman La-Roche); (Rx)

Interferon Alfa-2b (recombinant (IFN-alpha2; rIFN-a2; a-2-interferon) Powder for Injection: 5 million Units/vial; 10 million Units/vial; 18 million Units/vial; 25 million Units/vial & 50 million Units/vial in vials with a mL, 2 mL or 5 mL diluent/vial; Intron A® (Schering); (Rx)

Interferon Alfa-2b (recombinant (IFN-alpha2; rIFN-a2; a-2-interferon) Injection: 3 million Units/dose; 5 million Units/dose, & 10 million Units/dose in multidose pens; Intron A® (Schering); (Rx)

Interferon Alfa-2b (recombinant (IFN-alpha2; rIFN-a2; a-2-interferon) Solution for Injection: 3 million Units/vial, 5 million Units/vial; 10 million Units/vial; 18 million Units/vial & 25 million Units/vial in vials, Pak-3, -5, -10 (vials & syringes); & in multidose vials (22.8 million Units/3.8 mL/vial or 32 million Units/3.2 mL/vial); Intron A® (Schering); (Rx)

Interferon Alfa-N3 (human leukocyte derived) Injection: 5 million Units/mL (8 mg NaCl, 1.74 mg Na phosphate dibasic, 0.2 mg K phosphate monobasic, 0.2 mg KCl) in 1 mL vials; Alferon N ® (Interferon Sciences Inc.); (Rx)
wantaro, 獣医師
カテゴリ:
満足したユーザー: 5195
経験: 小動物臨床10年
wantaroをはじめその他名の猫カテゴリの専門家が質問受付中
質問者: 返答済み 4 年 前.
,参考になる回答、ありがとうございました。早速、実行したいと思います。
専門家:  wantaro 返答済み 4 年 前.

お大事にどうぞ

ユーザーの声:

 
 
 
  • 命が危ないから、すぐ病院に生きなさい、とご指導頂き、直ちに夜間診療に走り、尿道結石、並びに膀胱炎で、重篤な病状が見つかり、一命を取り止めました。本当に嬉しかったです。本日退院予定です。有難うございました。先生が、すぐ病院へ、とご指導して下さらなかったら、一日延ばしていたと思います。背中を押して下さった先生に大感謝です。 岐阜県大垣市 清水
< 前へ | 次へ >
  • 命が危ないから、すぐ病院に生きなさい、とご指導頂き、直ちに夜間診療に走り、尿道結石、並びに膀胱炎で、重篤な病状が見つかり、一命を取り止めました。本当に嬉しかったです。本日退院予定です。有難うございました。先生が、すぐ病院へ、とご指導して下さらなかったら、一日延ばしていたと思います。背中を押して下さった先生に大感謝です。 岐阜県大垣市 清水
  • 貴重なセカンドオピニオンをいただいた。 かかりつけ医師の診断結果を鵜呑みにしていたらペットは衰弱して死んでいた。このサイトでアドバイスを受けて、遠くでも良い医師の診断を受ける選択肢があることを知った。 今回のケースではギリギリ手遅れにならずに手術を受けることになった。地元に医師を軽んずる訳ではないが、別の専門医の意見を聞くことは重要と痛感した。 このサイトに出会えて良かった。かかりつけ医師の診断方法、投与薬、診断結果から技術不足を見抜いた。結局レントゲンをすれば原因はすぐわかることだったが、思い込みから実施しなかったと思われる。 いずれにせよ、このサイトの先生のアドバイスは納得のいく説明であった。 大阪府 別所
  • 緊急性があるな!!って思ったら仕事休んでも、夜の救急病院にでも行くと思いますが、あれ…!!何か様子がちょっと変か も…の状態が続き、仕事も忙しく、とにかく病院に 連れて行くのが大変!!!どうしようか迷いながら心配で仕事していても落ち着かない、もう一匹が病院に かかり2日間で五万、六万とお金がかかったばか り。そんな時ネットで調べていて、こ ちらにお世話になりました。救急では無く今の状態が飼い主の私自身が納得したかった。明け方でも夜中でも親切に対応して頂きそしていろんな症状も想定され納得しました。安心して仕事に出掛けれました。ありがとうございました。何かの時はまた利用させて頂きます。 東京都 藤田
  • まずは親身になって回答をして頂ける専門家であったこと。説明が簡潔でわかりやすく、質問者が気持ちの整理をしやすい配慮が伺えた。 岐阜県 石川
  • 短時間で的確なアドバイスを受けることができ、かつ、回答に対する質問に対しても直ちに真摯な回答が得られました。 大阪府高槻市 川嶋
  • 専門知識のある経験豊富な方に出会う機会のない人でも、このサイトで実現出来ることは素晴らしいことだと思いました。 専門家が辛抱強く回答をしてくださる姿勢にも感謝いたしました。 茨城県日立市 池田
 
 
 

専門家の紹介:

 
 
 
  • yasuyuki

    yasuyuki

    獣医師

    満足した利用者:

    207
    北里大院卒獣医学修士臨床経験20年以上
  • http://ww2.justanswer.com/uploads/YA/yasuyuki/2011-8-27_24733_SN3A0090.64x64.JPG yasuyuki さんのアバター

    yasuyuki

    獣医師

    満足した利用者:

    207
    北里大院卒獣医学修士臨床経験20年以上
  • http://ww2.justanswer.com/uploads/SH/shiratamaah/2011-8-29_12220_DSC0870.64x64.jpg shiratama_ah さんのアバター

    shiratama_ah

    獣医師

    満足した利用者:

    18
    勤務医として副院長を務めた後、都内で往診専門の動物病院を開院いたしました。
  • http://ww2.justanswer.com/uploads/SP/spacevet1/2011-11-6_141713_2011kt.64x64.png 高橋 賢 さんのアバター

    高橋 賢

    獣医師、医学博士

    満足した利用者:

    11
    医学研究歴11年
  • http://ww2.justanswer.com/uploads/LO/loverai0210/2011-9-6_22472_shirtF1.64x64.JPG loverai0210 さんのアバター

    loverai0210

    獣医師

    満足した利用者:

    676
    動物病院に勤務しています。主に犬猫の質問を受け付けております。
  • /img/opt/shirt.png japavet さんのアバター

    japavet

    獣医師

    満足した利用者:

    1497
    動物病院勤務歴6年
  • /img/opt/shirt.png issafd3s さんのアバター

    issafd3s

    獣医師

    満足した利用者:

    777
    北海道大学獣医学部卒業
  • /img/opt/shirt.png arinko さんのアバター

    arinko

    獣医師

    満足した利用者:

    68
    コンパニオンアニマルの臨床医療を16年しています。
 
 
 

猫 についての関連する質問